MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C . MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C , with a K d of 4.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines In Vitro MB710 (0-200 μM; 72 hours) shows relatively low toxicity against all cell lines tested at concentrations up to 60 μM, while showing initial selective viability reduction at higher concentrations. MB710 (72 hours) treats cancer cell lines NUGC3, NUGC4, WI38 and SW1088, with IC 50 s of 90, 120, >120, >120 μM, respectively. MB710 (0-120 μM; 72 hours; HUH-7 cells) shows stronger cytotoxic effects in presence of p53-Y220C. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: NUGC3 (mutant p53 Y220C), HUH-7 (mutant p53 Y220C), NUGC4 (p53 WT), HUH-6 cells (p53 WT) Concentration: 0-200 μM Incubation Time: 72 hours Result: Showed relatively low toxicity against all cell lines tested at concentrations up to 60 μM. NUGC3 was the most sensitive cell line. Form:Solid IC50& Target:Kd: 4 μM (p53-Y220C)